ZBTB7A functioned as an oncogene in colorectal cancer
- PDF / 1,305,600 Bytes
- 7 Pages / 595.276 x 790.866 pts Page_size
- 79 Downloads / 174 Views
RESEARCH ARTICLE
Open Access
ZBTB7A functioned as an oncogene in colorectal cancer Li Wang1†, Meng-Xia Zhang2†, Mei-Fang Zhang3* and Zi-Wei Tu4*
Abstract Background: Despite zinc finger and BTB domain-containing 7A (ZBTB7A) documented importance in multiple tumors, the function and clinical value in Colorectal cancer (CRC) remain elusive. The aim of this study was to evaluate the functional roles and the clinical value of ZBTB7A in CRC progression. Methods: The level of ZBTB7A was detected in a large cohort of CRC patients (n = 189) by immunohistochemistry (IHC), and we analyzed the diagnostic and prognostic value of the protein. In addition, the functional roles of ZBTB7A on CRC were explored in vitro and in vivo. Results: Survival analyses indicated that patients with high ZBTB7A expression made the prognosis worse (P = 0.024). Functionally, knockdown of ZBTB7A could markedly inhibit tumor proliferation in vitro and in vivo, whereas ZBTB7A overexpression displayed the opposite results. Conclusions: ZBTB7A was associated with poor survival outcomes and functioned as an oncogene in CRC patients, indicating that it is a potential prognostic biomarker and therapeutic target for CRC patients. Keywords: ZBTB7A, Oncogene, Colorectal cancer (CRC), Prognosis, Biomarker
Background With nearly 1.8 million new cases and 900,000 deaths annually, colorectal cancer (CRC) is the third most popular malignant tumor worldwide [1, 2]. Like other cancers, CRC is induced by a multistep genetic disorder and involves accumulation of both genetic and epigenetic changes [3, 4]. Nowadays, the major treatment methods for CRC include surgical resection, radiotherapy, chemotherapy, targeted molecular therapy, and immunotherapy, which have a great development over the last few decades [5, 6]. However, the recurrence and metastasis occur in numerous advanced patients who * Correspondence: [email protected]; [email protected] † Li Wang and Meng-Xia Zhang contributed equally to this work. 3 Department of Pathology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, Guangdong, China 4 Department of Radiotherapy, Jiangxi Cancer Hospital, Medical College, Nanchang University, No. 519, Beijing East Road, Qingshan Lake District, Nanchang 330029, Jiangxi, China Full list of author information is available at the end of the article
undergo systemic therapy and the survival rates for advanced patients remains low. Still, our knowledge on CRC is limited [7, 8]. Thus, the further identification of the molecular mechanisms of CRC carcinogenesis and more effective treatment approaches are urgently required to increase early detection and reduce mortality from CRC. Zinc finger and BTB domain-containing 7A (ZBTB7A, also known as FBI, POKEMON and LRF) is a member of the POZ/BTB and Krüppel (POK) family of transcriptional repressors [9, 10]. The gene was firstly identified by Davies JM et al. in 1999 and encodes a 62 kDa Znfinger protein [11].
Data Loading...
